Panitumumab

Panitumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Epidermal growth factor receptor (EGFR)
Clinical data
Trade names	Vectibix
Other names	ABX-EGF
AHFS/Drugs.com	Monograph
MedlinePlus	a607066
License data	EU EMA: by INN; US DailyMed: Panitumumab;
Routes of; administration	Intravenous
ATC code	L01FE02 (WHO) ;
Legal status
Legal status	US: WARNINGRx-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	~9.4 days (range: 4-11 days)
Identifiers
CAS Number	339177-26-3 ;
DrugBank	DB01269 ;
ChemSpider	none;
UNII	6A901E312A;
KEGG	D05350;
ChEMBL	ChEMBL1201827 ;
PDB ligand	5sx4 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C6398H9878N1694O2016S48
Molar mass	144324.12 g·mol−1
	(what is this?) (verify)

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

Panitumumab is manufactured by Amgen and was originally developed by Abgenix Inc.

In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.